Sponsors (3)
The bill boosts federal research, prevention, safety rules, and state support to reduce youth cannabis use and impaired driving and to clarify product regulation, but it raises federal spending, increases compliance and enforcement risks for businesses and individuals, and creates privacy and implementation trade‑offs that may disproportionately affect marginalized communities.
Children and adolescents (and their families) face reduced access to intoxicating THC-containing cannabinoid products and stronger prevention efforts, due to explicit under‑21 bans, labeling/serving-size rules, and funded prevention and education campaigns.
Federal research, surveillance, and data collection are expanded (CDC funding increases, DOT study, annual reports), improving evidence for policy, prevention, and impaired‑driving responses nationwide.
States and law enforcement receive dedicated grant funding and model practices to improve testing, courts, and responses to cannabis-impaired driving, which can reduce roadway harms and improve case quality.
All taxpayers face higher federal spending (hundreds of millions across FY2026–2030 plus annual authorizations) to fund expanded surveillance, studies, campaigns, and grants.
Small manufacturers and retailers face higher compliance costs and legal exposure from broad cannabinoid definitions, civil penalties (up to $15,000 per violation and higher for knowing violations), seizure and no‑sale orders that could shutter businesses.
Expanded enforcement, testing, and grant-supported prosecutions may increase arrests and criminal-justice impacts for drivers and others, and prioritizing areas with historical arrest disparities risks reinforcing stigma or uneven enforcement.
Based on analysis of 6 sections of legislative text.
Defines 'cannabis' and 'cannabinoid' in federal law, brings many cannabinoid products under FDA authority, expands public-health surveillance and youth-prevention grants, and funds impaired-driving research and state grants.
Introduced December 15, 2025 by Ronald Lee Wyden · Last progress December 15, 2025
Brings cannabinoid products explicitly under the Federal Food, Drug, and Cosmetic Act by adding statutory definitions of “cannabis,” “cannabinoid,” and “cannabinoid product,” and clarifies which cannabis-derived materials are excluded. Expands federal public-health surveillance to capture cannabis-related adverse effects and funds new and existing grant programs for youth prevention, data collection, and community interventions. Directs DOT and NHTSA to study and fund efforts to prevent cannabis-impaired driving, start a national roadside survey, develop best practices and national campaigns, and explore a national impairment standard, with multi-year grant funding and federal appropriations for implementation.